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Aims Amphetamine intake is associated with acute vascular syndromes. Since these events are caused by arterial throm-
bosis and this in turn is triggered by tissue factor (TF), this study examines whether amphetamines regulate TF in
human endothelial cells.
Methods
and results
Amphetamine (1027–1024 mol/L) enhanced thrombin- and tumour necrosis factor (TNF)-a-induced as well as basal
TF expression (P ¼ 0.029, 0.0003, and 0.003 at maximal concentration), and TNF-a-induced plasminogen activator
inhibitor (PAI)-1 expression (P ¼ 0.003), whereas tissue factor pathway inhibitor expression was impaired (P ¼ 0.008).
Similarly, 3,4-methylenedioxymethamphetamine (1027–1024 mol/L) enhanced TF expression (P ¼ 0.046). These
effects were paralleled by an increased TF activity (P ¼ 0.002); moreover, clotting time of human plasma was accelerated
by supernatant from amphetamine-treated cells (P ¼ 0.03). Amphetamine enhanced TF mRNA expression via phos-
phorylation of the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinase (ERK) and p38
(P ¼ 0.03 and 0.033), but not c-Jun NH2-terminal kinase (JNK; P ¼ 0.81). The effect of amphetamine on TF expression
was abrogated by the dopamine D4 receptor antagonists L-745,870 and L-750,667, but not D2 or D3 receptor
antagonists; furthermore, L-745,870 blunted the amphetamine-induced activation of ERK and p38, but not JNK.
Conclusion Amphetamines induce endothelial TF expression via stimulation of dopamine D4 receptor and activation of the
MAPKs p38 and ERK. These effects occur at clinically relevant amphetamine concentrations and may account for
the increased incidence of acute vascular syndromes after amphetamine consumption.
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Introduction
In the Western civilization, intake of psychostimulants such as
amphetamine and 3,4-methylenedioxymethamphetamine (MDMA,
‘Ecstasy’) has risen dramatically over the past decade; as a conse-
quence, this phenomenon has now turned into a major public
burden.1 The problem is aggravated by the fact that the majority
of consumers are young (45 years) and thus often faced with
unexpected acute cardiovascular events.2 Indeed, numerous
publications report amphetamine-associated acute vascular syn-
dromes including myocardial infarction and ischaemic stroke.3 –8
The pathogenesis of amphetamine-related acute cardiovascular
events is still uncertain. Vasospasm and prothrombotic state have
been postulated as aetiological factors, but no solid evidence is avail-
able to support these assumptions.3,4,9 The combination of vasos-
pasm and thrombosis does indeed seem to play a role in coronary
artery occlusion, indicating a dynamic interaction of vasoconstriction
and thrombus formation in acute vascular syndromes.10 Further,
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substances suspected to promote vasospasm, such as histamine and
cocaine, are known to induce the endothelial expression of tissue
factor (TF).11,12 Tissue factor is the main trigger of coagulation and
crucially involved in arterial thrombus formation, the central event
in acute vascular syndromes.13 In this context, it is important to
note that amphetamines are known to activate mitogen-activated
protein kinases (MAPKs), the major regulators of endothelial TF
expression, in neuronal cells.14 On the basis of these facts, we hypoth-
esized that amphetamine may induce TF expression. Hence, this study
was designed to examine the effect of amphetamines on TF
expression in human vascular endothelial cells.
Methods
Cell culture
Human aortic endothelial cells (HAECs; Clonetics, Allschwil,
Switzerland) were cultured as described.15 Cells were grown to conflu-
ence and were then serum withdrawn for 24 h by using EBM medium
(Cambrex) supplemented with 0.5% FCS, before stimulation with 5 ng/
mL tumour necrosis factor (TNF)-a (R&D, Minneapolis, MN, USA) or
1 U/mL thrombin (Sigma-Aldrich, Buchs, Switzerland) (Figure 1). Cells
were pre-treated with amphetamine (Lipomed, Arlesheim, Switzerland)
or MDMA (Sigma-Aldrich) for 60 min before stimulation with TNF-a.
Dopamine, L-750,667, L-745,870, raclopride (all from Sigma-Aldrich),
and NGB 2904 (Tocris Bioscience, Ellisville, MO, USA) were added to
the dishes 60 min before stimulation (Figure 1). Cytotoxicity was assessed
with a colorimetric assay to detect lactate dehydrogenase (LDH) release
(Roche, Basel, Switzerland). The use of MDMA in this study was approved
by the Swiss Health Authority (reference: AB-8/5-BetmG-07.001315).
Western blot
Protein expression was determined by western blot analysis as
described.16 Antibodies against human TF and tissue factor pathway
inhibitor (TFPI; both from American Diagnostica, Stamford, CT, USA)
were used at 1:2000 dilution. Antibody against plasminogen activator
inhibitor (PAI-1; Santa Cruz) was applied at 1:4000 dilution. Antibodies
against phosphorylated p38 MAPK (p38), p44/42 MAPK [extracellular
signal-regulated kinase (ERK)], and c-Jun NH2-terminal kinase (JNK; all
from Cell Signaling, Danvers, MA, USA) were used at 1:1000, 1:5000,
and 1:1000 dilution, respectively. Antibodies against total p38, ERK, and
JNK (all from Cell Signaling) were used at 1:3000, 1:2000, and 1:1000
dilution, respectively. Antibodies against Thr-34 and Thr-75 phosphory-
lated as well as against total dopamine-and-cAMP-regulated phosphopro-
tein 32 (DARPP-32) (Cell Signaling) were used at 1:1000 dilution.
Anti-goat glyceraldehyde-3-phosphate dehydrogenase antibody
(Chemicon, Temecula, CA, USA) was applied to ensure equal protein
loading (1:20 000 dilution). Proteins were detected with a horseradish
peroxidase-linked secondary antibody (Amersham, Munich, Germany).
Real-time polymerase chain reaction
Total RNA was extracted from HAEC using TRIzol Reagent (Invitro-
gen). Conversion of total cellular RNA to cDNA was carried out
Figure 1 Study conduct of the in vitro experiments.
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with Moloney murine leukaemia virus reverse transcriptase and
random hexamers (Amersham Bioscience) in a final volume of 33 mL
using 4 mg of cDNA. All real-time polymerase chain reaction (PCR)
experiments were performed in triplicate using the SYBR Green
JumpStart kit (Sigma, Saint Louis, MO, USA) in an MX3000P PCR
cycler (Stratagene, Amsterdam, The Netherlands). Each reaction
(25 mL) contained 2 mL cDNA, 10 pmol of each primer, 0.25 mL of
internal reference dye, and 12.5 mL of JumpStart Taq ReadyMix (con-
taining buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase, and
JumpStart Taq antibody). The following primers were used: for TF:
sense: 50-TCCCCAGAGTTCACACCTTACC-30 (bases 508–529 of
F3 cDNA; NCBI no. NM 001993), antisense: 50-CCTTTCTCC
TGGCCCATACAC-30 (bases 843–863 of TF cDNA; NCBI no. NM
001993); for human D4 dopamine receptor: sense: 50-CCCACCCC
AGACTCCACC-30 (bases 963–980 of DRD4 cDNA; NCBI no. NM
000797), antisense: 50-GAACTCGGCGTTGAAGACAG-30 (bases
1202–1221 of DRD4 cDNA; NCBI no. 000797); and for human
L28: sense: 50-GCATCTGCAATGGATGGT-30, antisense: 50-CCTT
TCTCCTGGCCCATACAC-30. The amplification programme con-
sisted of 1 cycle at 958C for 10 min, followed by 35 cycles with a dena-
turing phase at 958C for 30 s, an annealing phase at 608C for 1 min,
and an elongation phase at 728C for 1 min. A melting curve analysis
was performed after amplification to verify the accuracy of the ampli-
con. Polymerase chain reaction products were also analysed on an
ethidium bromide-stained 1.5% agarose gel. In each real-time PCR
run, a calibration curve was included that was generated from serial
dilutions of the respective purified amplicons. Tissue factor mRNA
stability was assessed in the presence of the transcriptional inhibitor
actinomycin D (10 mg/mL, Sigma-Aldrich), which was added 2 h after
TNF-a stimulation. Cells were harvested for RNA extraction at
various time points (0–3 h) following actinomycin D treatment. The
copy numbers for TF obtained in the real-time PCR analysis were
normalized to those of L28, and the values are presented as per
cent of the TNF-a alone group.
Gene silencing through siRNA transfection
Three siRNA sequences specific for the human dopamine receptor 4
(D4) were applied for knocking down D4 expression using the
N-TERTM Nanoparticle siRNA Transfection System (Sigma). These
siRNA sequences were as follows: siRNA 1 (sense: 50-CCGCCUCC
AUCUUCAACCUdTdT-30; antisense: 50-AGGUUGAAGAUGGAGG
CGGdTdT-30); siRNA 2 (sense: 50-CCCUCAUGGCCAUGGACGU
dTdT-30; antisense: 50-ACGUCCAUGGCCAUGAGGGdTdT-30); and
siRNA 3 (sense: 50-GCCUCCAUCUUCAACCUGUdTdT-30; antisense:
50-ACAGGUUGAAGAUGGAGGCdTdT-30). Briefly, cells were trans-
fected with a 15 nM siRNA Nanoparticle Forming Solution and incu-
bated with transfection serum-free medium for the following 4 h at
378C. Subsequently, cells were cultured in the serum-containing
growth medium for 24–48 h at 378C.
Tissue factor activity
Tissue factor activity was analysed at the luminal surface of adherent
endothelial cells and in whole-cell lysates of HAEC using a colorimetric
assay (American Diagnostica). TF/FVIIa converted factor X to factor Xa,
which was measured by its ability to metabolize a chromogenic sub-
strate. A standard curve with lipidated human TF was performed to
assure that measurements were taken in the linear range of detection.
Clotting time
Clotting time was assessed using a Start fibrometer. Fifty microlitres of
supernatant from HAECs were harvested and incubated with 50 mL of
citrated human plasma for 1 min. Coagulation was initiated by the
addition of 25 mM calcium chloride followed by analysis of clotting time.
Statistics
Differences between mean data were compared by the non-parametric
Mann–Whitney test and Jonckheere–Terpstra test, respectively, for
non-Gaussian variables; however, due to the low number of experiments,
those tests must not refer to the usual normal approximation. In case of a
significant global test (more than two groups), Dunn’s multiple compari-
son test was used for pairwise group comparison. All statistical decisions
were made two-tailed with a 95% confidence interval. Data are reported
as mean+ SEM. All tests used exact probability distributions. A two-
tailed P-value of 0.05 was chosen as cut-off for statistical significance at
hypothesis testing. Statistical analyses were performed using GraphPad
Prism software, version 4.03 (GraphPad Software Inc., La Jolla, CA,
USA) and SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Amphetamines enhance tissue factor
protein expression and activity
Human aortic endothelial cells were stimulated with TNF-a (5 ng/
mL) or thrombin (1 U/mL) for 5 h in the presence or absence of
amphetamines (Figure 1). Amphetamine (1027–1024 mol/L)
enhanced TNF-a-induced TF expression in a concentration-
dependent manner reaching a 1.8-fold induction (n ¼ 7;
P ¼ 0.0003; Mann–Whitney test; Figure 2A; Table 1). Similarly,
amphetamine enhanced thrombin-induced TF expression by
1.6-fold (n ¼ 4; P ¼ 0.029; Mann–Whitney test; Figure 2C; Table 1)
and basal TF expression by 2.2-fold (n ¼ 7; P ¼ 0.003; Mann–
Whitney test; Figure 2D; Table 1). Similar to amphetamine, MDMA
(1027–1024 mol/L) enhanced TF expression by 1.7-fold at
maximum concentration when compared with TNF-a alone (n ¼ 4;
P ¼ 0.046; Mann–Whitney test; Figure 2B; Table 1). The effect of
amphetamine and MDMA on TF protein expression was paralleled
by an increased TF surface activity both in TNF-a-stimulated cells
(n ¼ 5–6; P ¼ 0.002 and 0.008, respectively; Mann–Whitney test;
Figure 3A and B; Table 1) and under basal conditions (n ¼ 6;
P ¼ 0.002; Mann–Whitney test; Figure 3D; Table 1). Amphetamine
induced a similar relative increase in TF surface activity and TF whole-
cell activity (n ¼ 5; P ¼ 0.004; Mann–Whitney test; Figure 3C; Table 1).
Amphetamines are not toxic
To control for toxic effects, HAECs were treated with increasing con-
centrations of amphetamine or MDMA for 6 h. Morphological exam-
ination did not reveal any changes (n ¼ 9; data not shown); moreover,
no signs of toxicity were detected by LDH release for any concen-
tration of amphetamine or MDMA used (n ¼ 9; data not shown).
Amphetamine accelerates clotting time
of human plasma
To assess the functional relevance of amphetamine-induced TF
expression, the effect of supernatant from amphetamine-treated
HAECs on clotting time of human plasma was assessed. Clotting
time was accelerated by supernatant from cells treated with amphet-
amine both under basal conditions (n ¼ 4; P ¼ 0.03; Mann–Whitney
test; Supplementary material online, Figure S1; Table 1) and after
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stimulation with TNF-a (n ¼ 6; P ¼ 0.002; Mann–Whitney test; Sup-
plementary material online, Figure S1; Table 1).
Amphetamine impairs tissue factor
pathway inhibitor and increases
plasminogen activator inhibitor-1
expression
Increasing concentrations of amphetamine (1027–1024 mol/L)
inhibited expression of TFPI in TNF-a- and thrombin-stimulated
HAECs resulting in a 45 and 36% reduction, respectively
(n ¼ 4–5; P ¼ 0.008 and 0.03, respectively; Mann–Whitney test;
Figure 4B and C; Table 1). A similar effect was observed under
basal conditions (n ¼ 4; P ¼ 0.03; Mann–Whitney test; Figure 4A;
Table 1). In contrast, amphetamine (1024 mol/L) increased endo-
thelial PAI-1 expression following TNF-a stimulation (n ¼ 6;
P ¼ 0.003; Mann–Whitney test; Table 1).
Amphetamine enhances tissue factor
mRNA expression without affecting
mRNA stability
Real-time PCR demonstrated that TF mRNA expression was
induced after 2 h of TNF-a stimulation (n ¼ 4; P ¼ 0.029;
Figure 2 Amphetamines enhance endothelial tissue factor protein expression. (A) Amphetamine enhances tumour necrosis factor-a-induced
tissue factor protein expression. *P, 0.05 vs. tumour necrosis factor-a alone. (B) 3,4-Methylenedioxymethamphetamine enhances tumour necro-
sis factor-a-induced tissue factor protein expression. *P, 0.05 vs. tumour necrosis factor-a alone. (C) Amphetamine enhances thrombin-induced
tissue factor protein expression. *P, 0.05 vs. tumour necrosis factor-a alone. (D) Amphetamine induces basal tissue factor protein expression.
*P, 0.05 vs. unstimulated control. All blots are normalized to glyceraldehyde-3-phosphate dehydrogenase expression.
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Mann–Whitney test; Figure 5A). Treatment with amphetamine
enhanced TNF-a-induced TF mRNA expression in a
concentration-dependent manner reaching a maximal induction
of 2.1-fold (n ¼ 4; P ¼ 0.032; Mann–Whitney test; Figure 5A;
Table 1). Amphetamine did not affect the stability of TF mRNA
under these conditions (n ¼ 4; Figure 5B).
Amphetamine enhances
mitogen-activated protein kinase
activation
To assess whether amphetamine alters MAPK activation, HAECs
were examined at different time points after cytokine stimulation.
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Table 1 Group comparison by the Mann–Whitney test
Parameter Amphetamine (1024 M),
mean+ SEM
MDMA (1024 M),
mean+ SEM
Dopamine (1024 M),
DRA/siRNA,
mean+ SEM
n P-value of
Mann–Whitney/
Jonckheere–Terpstra
TF protein expression
TNF-a stimulation
(amphetamine)
181.1+9.0 7 0.0003
TNF-a stimulation
(MDMA)
169.5+12.5 4 0.046
Thrombin stimulation 160.1+23 7 4 0.029
Basal 216.7+34.6 7 0.003
TNF-a stimulation
(dopamine)
215.5+49.8 6 0.002
Dopamine 2R
antagonist
174.0+18.6 208.5+42.1 4 1.0a
Dopamine 3R
antagonist
174.0+18.6 188.5+42.7 4 0.46a
Dopamine 4R
antagonist
174.0+18.6 67.9+20.0 5 0.002a
TFPI expression
TNF-a stimulation 56.5+9.3 5 0.008
Thrombin stimulation 74.6+9.6 4 0.03
Basal 61.5+4.7 4 0.03
PAI-1 expression
(TNF-a)
207.2+24.7 6 0.003
MAPK phosphorylation
Pho-ERK 159.6+9.1 4 0.03
Pho-p38 110.7+16.4 7 0.033
Pho-JNK 102.1+14.02 4 0.81
TF surface activity
TNF-a stimulation
(amphetamine)
159.3+9.1 6 0.002
TNF-a stimulation
(MDMA)
127.0+5.3 5 0.008
Basal 168.0+20.9 6 0.002
Whole-cell TF activity
(TNF-a)
147.1+10.3 5 0.004
Clotting time
Basal 79.5+5.3 4 0.03
TNF-a stimulation 85.6+2.8 6 0.002
TF mRNA expression 203.6+22.3 4 0.029
D4R siRNA
transfection
180.4+15.2 99.1+19.8 5 0.03
Data are presented as mean+ SEM (per cent vs. control group). DRA, dopamine receptor antagonist.
aJonckheere–Terpstra’s test for multiple group comparison was applied. In case of a significant global test, Dunn’s multiple comparison test was used for pairwise group
comparison.
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The MAPKs p38, ERK, and JNK were transiently activated by
TNF-a (n ¼ 4; Figure 7). Amphetamine enhanced phosphorylation
of p38 and ERK (n ¼ 4–7; P ¼ 0.033 and 0.03, respectively; Mann–
Whitney test; Figure 7A and B; Table 1), whereas that of JNK
remained unaffected (n ¼ 4; P ¼ 0.81; Mann–Whitney test;
Figure 7A and B). No significant change in total expression of
MAPKs was observed at any time point with or without amphet-
amine. The MAPK inhibitors SB203580, PD98059, and SP600125,
which specifically act on p38, ERK, and JNK, respectively, impaired
TF expression after TNF-a stimulation (n ¼ 4; P, 0.05 for TNF-a
alone vs. each inhibitor; Mann–Whitney test; Figure 7C). Phos-
phorylation of DARPP-32 was not altered in the presence or
absence of amphetamine (data not shown). Mitogen-activated
protein kinase inhibitors were not toxic as assessed by LDH
release measured 5 h after addition of TNF-a (n ¼ 3; data not
shown).
Dopamine D4 receptor mediates the
effect of amphetamine on tissue factor
Some of the psychotropic effects of amphetamine are known to be
mediated by dopamine receptors. Endothelial cells express dopa-
mine D2, D3, and D4 receptors, and these receptors are known
to modulate endothelial activation. Expression of the dopamine
D4 receptor in HAECs was confirmed by PCR (n ¼ 5; data not
shown). Dopamine indeed enhanced TNF-a-induced TF
expression in HAECs (n ¼ 6; P ¼ 0.002; Mann–Whitney test;
Figure 6A; Table 1). To determine whether dopamine receptors
are involved in amphetamine-induced TF expression, cells were pre-
treated with amphetamine, the D2 receptor antagonist raclopride,
the D3 receptor antagonist NGB 2904, or the D4 receptor antag-
onists L-745,870 and L-750,667. Pre-treatment with L-745,870
abrogated amphetamine-induced TF expression (n ¼ 5; P ¼ 0.002;
Figure 3 Amphetamine induces tissue factor activity. (A) Amphetamine enhances tumour necrosis factor-a-induced tissue factor surface
activity. *P, 0.05 vs. tumour necrosis factor-a alone. (B) 3,4-Methylenedioxymethamphetamine enhances tumour necrosis factor-a-induced
tissue factor surface activity. *P, 0.05 vs. tumour necrosis factor-a alone. (C) Amphetamine induces a similar relative increase in luminal
surface activity and whole-cell activity of tissue factor. P, 0.05 vs. control. (D) Amphetamine induces basal tissue factor surface activity.
*P, 0.05 vs. unstimulated control.
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Jonckheere–Terpstra test; Figure 6B; Table 1), and a similar effect
was observed with L-750,667 (n ¼ 3; P ¼ 0.03; Jonckheere–
Terpstra test; data not shown). In contrast, the effect of amphet-
amine remained unaltered by pre-treatment with raclopride or
NGB 2904 (n ¼ 4; P ¼ 1.0 and 0.46, respectively; Jonckheere–
Terpstra test; Figure 6C and D; Table 1). When the D4 receptor
gene was silenced through siRNA transfection, the effect of
amphetamine on TF expression was abrogated, whereas non-
targeting siRNA had no effect on amphetamine-induced TF
expression (n ¼ 5; P ¼ 0.03 for amphetamine in non-targeting
siRNA-transfected cells vs. amphetamine in D4R siRNA-
transfected cells; Mann–Whitney test; Figure 6E). Blocking the
dopamine D4 receptor with L-745,870 (1025 mol/L) abrogated
the amphetamine-induced phosphorylation of p38 (n ¼ 4;
P ¼ 0.03 for amphetamine and L-745,870 vs. amphetamine alone;
Mann–Whitney test; Figure 8A) and ERK (n ¼ 4; P ¼ 0.03
for amphetamine and L-745,870 vs. amphetamine alone;
Mann–Whitney test; Figure 8B), whereas activation of JNK
remained unaffected (n ¼ 4; P ¼ 0.34 for amphetamine and
L-745,870 vs. amphetamine alone; Mann–Whitney test;
Figure 4 Amphetamine inhibits endothelial tissue factor
pathway inhibitor protein expression. (A) Amphetamine inhibits
basal tissue factor pathway inhibitor protein expression.
*P, 0.05 vs. unstimulated control. (B) Amphetamine inhibits
tissue factor pathway inhibitor protein expression in tumour
necrosis factor-a-stimulated cells. *P, 0.05 vs. tumour necrosis
factor-a alone. (C) Amphetamine inhibits tissue factor pathway
inhibitor protein expression in thrombin-stimulated cells.
*P, 0.05 vs. thrombin alone.
Figure 5 Amphetamine enhances endothelial tissue factor
mRNA expression without affecting mRNA stability. (A) Amphet-
amine enhances tumour necrosis factor-a-induced tissue factor
mRNA expression. *P, 0.05 vs. tumour necrosis factor-a
alone. Values are determined by real-time polymerase chain reac-
tion, indicated as per cent of tumour necrosis factor-a alone, and
normalized to L28 expression. (B) Amphetamine (1024 M) does
not affect tissue factor mRNA stability. Tissue factor mRNA
copies are normalized to L28 expression and expressed as per
cent of tumour necrosis factor-a.
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Figure 6 Amphetamine enhances endothelial tissue factor expression via dopamine D4 receptor. (A) Dopamine enhances tumour necrosis
factor-a-induced endothelial tissue factor expression. *P, 0.05 vs. tumour necrosis factor-a alone. (B) The dopamine D4 receptor antagonist
L-745,870 abrogates amphetamine-induced tissue factor expression. *P, 0.05 vs. amphetamine alone. (C ) The effect of amphetamine remains
unaltered by the D2 receptor antagonist raclopride. (D) The effect of amphetamine remains unaltered by the D3 receptor antagonist NGB
2904. (E) Amphetamine-enhanced tissue factor expression is abrogated when D4 receptor gene is silenced through siRNA transfection.
*P, 0.05 vs. vs. amphetamine in D4R siRNA-transfected cells.
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Figure 8C). L-745,870 alone did not affect the TNF-a-induced acti-
vation of MAPKs (n ¼ 4; Figure 8). Total expression of MAPKs
remained unchanged at all time under all conditions (n ¼ 4; data
not shown). Lactate dehydrogenase release did not reveal any
cytotoxic effect of dopamine, raclopride, NGB 2904, L-745,870,
or L-750,667 (n ¼ 3; data not shown).
Discussion
Amphetamine consumption can lead to death due to cardiovascular
events and is becoming an increasingly serious worldwide concern.
Indeed, data from more than 30 case reports and 8 epidemiological
studies support this tendency. Amphetamine-associated adverse
Figure 7 Amphetamine enhances endothelial tissue factor expression via mitogen-activated protein kinase activation. (A) Phosphorylation
pattern of mitogen-activated protein kinases p38, extracellular signal-regulated kinase, and c-Jun NH2-terminal kinase following amphetamine
treatment in tumour necrosis factor-a-stimulated cells. (B) Mitogen-activated protein kinase activation after 15 min of amphetamine treatment,
expressed as an increase over tumour necrosis factor-a alone. *P, 0.05 vs. tumour necrosis factor-a alone. (C) The mitogen-activated protein
kinase inhibitors PD98059, SB203580, and SP600125, specifically inhibiting extracellular signal-regulated kinase, p38, and c-Jun NH2-terminal
kinase, respectively, impair tissue factor expression after tumour necrosis factor-a stimulation. *P, 0.05 for tumour necrosis factor-a
alone vs. each inhibitor.
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cardiovascular events mostly occur in relatively young individuals
with no previous history of cardiovascular disease. Consistent
with this observation, myocardial ischaemia with angiographically
normal coronary arteries is documented in amphetamine consu-
mers.2,17 A recent report described severe anterior myocardial
infarction with pump failure due to proximal thrombotic occlusion
of the LAD in a 28-year-old amphetamine consumer.18 Similar
reports have demonstrated intravascular thrombosis, either angio-
graphically or in post-mortem examination, in such patients.18,19 In
the present study, amphetamines are shown to induce TF
expression and surface activity in human endothelial cells; this
effect occurred at the transcriptional level and was mediated
through the dopamine D4 receptor leading to activation of the
MAPKs p38 and ERK. Since TF is the key trigger of thrombosis,
our observations offer a potential mechanism for the occurrence
of acute vascular syndromes in amphetamine consumers.
The concentrations applied in the present study are within the
plasma range observed in vivo; indeed, a plasma concentration of
5  1026 mol/L (1.1 mg/mL) was measured 6 h following MDMA
intake in a subject who developed massive thrombosis of the
right coronary artery.19 However, there is a large variability of
amphetamine plasma levels in patients presenting to the
emergency department, and up to 100-fold higher plasma con-
centrations in the range of 0.4–84.0 mg/mL for MDMA and
0.2–11.3 mg/mL (8  1025 mol/L) for amphetamine were
measured in amphetamine victims.20
In contrast to cocaine, amphetamine induced TF expression and
activity in both quiescent and cytokine-stimulated endothelial
cells.12,21– 23 Considering that the endothelium plays a pivotal
role in modulating the haemostatic balance, this observation adds
on to the evidence that amphetamine may trigger thrombus for-
mation in the absence of inflammatory alterations, as it may
occur in young amphetamine consumers. Furthermore, amphet-
amine enhanced TF expression in response to TNF-a, an inflam-
matory cytokine known to induce TF expression in endothelial
cells.13 Hence, amphetamines may up-regulate TF expression in
an inflammatory environment as it is observed in patients
exposed to cardiovascular risk factors, but without clinically mani-
fest atherosclerosis. Inflammation is indeed an important trigger for
the pathogenesis of arterial thrombosis,24 and inflammatory
markers such as C-reactive protein are significantly raised in
patients suffering from myocardial infarction at a young age.25 In
addition, the enhancing effect of amphetamine on thrombin-
induced TF expression suggests that amphetamine may not only
induce, but also amplify, thrombus formation converting a small
and clinically non-significant thrombus into an occlusive thrombo-
sis leading to an acute vascular syndrome.
Tissue factor activity is counterbalanced by TFPI, and the equili-
brium of these two factors is indeed essential in determining
thrombus formation.11,13 Besides its effects on TF, amphetamine
reduced endothelial TFPI, in both quiescent and TNF-a- or
thrombin-stimulated cells, indicating that the effect of amphet-
amine on TFPI does not depend on the activation status of the
cells. Moreover, in parallel to enhancing TF and decreasing TFPI,
amphetamine increased TNF-a-induced PAI-1 expression. Plasmi-
Figure 8 Amphetamine activates p38 and extracellular signal-
regulated kinase via dopamine D4 receptor. Blocking of the
dopamine D4 receptor with L-745,870 abolishes amphetamine-
induced activation of p38 and extracellular signal-regulated
kinase, whereas c-Jun NH2-terminal kinase phosphorylation
remains unaffected. *P, 0.05 vs. amphetamine alone.
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nogen activator inhibitor-1 is a serpin suppressing fibrinolysis by
inhibiting the activity of tissue plasminogen activator. Therefore,
amphetamine would indeed be expected to exert potent pro-
thrombotic actions in vivo by modulating different mediators of
haemostasis.
The functional relevance of the enhanced TF activity in
amphetamine-treated HAECs was underlined by the observation
that supernatant from amphetamine-treated cells accelerated clot-
ting time of human plasma; this effect occurred with cells treated
with amphetamine under both basal conditions and after cytokine
stimulation. These data, although performed in vitro, add on to the
evidence that amphetamine may trigger thrombus formation in
amphetamine consumers by enhancing coagulation.
Dopamine receptors play a role in mediating the behavioural
effects of amphetamine.26– 28 Earlier studies have convincingly
shown that blockade of dopamine D4 receptor in rats prevents
the acute stimulatory effects of amphetamine29 and dopamine
receptor blockade in mice attenuates amphetamine-induced
hyperlocomotion.28 Although many studies have investigated
amphetamine-mediated signalling in the brain, no efforts have
been made in identifying amphetamine-induced events in peripheral
cells. Dopamine receptors are expressed in endothelial cells, can
activate them, and mediate effects on coagulation factors.30–32
Tissue factor induction by amphetamine was indeed abrogated
by dopamine D4 receptor antagonists or by silencing the D4
receptor gene through siRNA transfection. In line with this obser-
vation, expression of this receptor in human endothelial cells was
confirmed; furthermore, its activation by dopamine was able to
induce endothelial TF expression. Considering the very similar
chemical structure of amphetamine and dopamine, it is possible
that amphetamine directly activates endothelial dopamine recep-
tors; alternatively, amphetamine may increase locally synthesized
extracellular dopamine by blocking dopamine transporters, as pre-
viously described in neuronal cells.33,34 Most of the dopamine is
indeed produced in non-neuronal locations such as renal tubules
and endothelial cells of various organs;35– 37 the latter being under-
lined by the identification of L-DOPA decarboxylase by RT–PCR
in cultured endothelial cells.32
Tissue factor expression in response to a variety of stimuli is
mediated by MAPK activation leading to increased TF transcrip-
tion.13 Amphetamine indeed enhanced activation of p38 and
ERK, but not JNK, resulting in enhanced TF mRNA expression;
TF mRNA stability remained unaltered under these conditions.
Inhibition of p38 and ERK impaired TF expression in response to
TNF-a, confirming that the effect of amphetamine on p38 and
ERK phosphorylation mediates the increase in TF expression.
This signal transduction profile of amphetamine is consistent
with recent observations demonstrating that p38 and ERK, but
not JNK, are required for mediating amphetamine-induced forms
of reward-related learning in the prefrontal cortex.14 Blocking of
the dopamine D4 receptor abolished activation of p38 and ERK,
but not JNK, suggesting that amphetamine leads to activation of
p38 and ERK via the dopamine D4 receptor. In line with this
interpretation, stimulation of the dopamine D4 receptor produced
a time- and dose-dependent increase in ERK activity in several
brain regions.38,39 Not surprisingly, MAPKs, in particular the ERK
pathway, have been described as a key molecular process in
selective brain regions in response to amphetamine, and pharma-
cological manipulation of the ERK pathway has been proposed as
a potential treatment strategy for drug addiction.40
The present in vitro study has several limitations. We have not
studied all the mechanism potentially influencing dopamine recep-
tor signalling. Thus, further studies are needed to understand the
molecular mechanism by which dopamine receptor signalling is
involved in the regulation of haemostasis and vascular biology.
Moreover, animal and clinical studies need to clarify whether an
increased TF activity indeed accounts for the effects of amphet-
amines on thrombus formation in vivo.
In summary, this study demonstrates that amphetamine leads to
an increase in endothelial TF expression and activity with a parallel
decrease in TFPI expression. This effect is mediated by the dopamine
D4 receptor and activation of the MAPKs p38 and ERK. These find-
ings may offer a mechanistic insight regarding amphetamine-induced
acute cardiovascular events.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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